Drugs / Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection
Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT05761717 Background | Apr 2023 → Mar 2025 | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05761717 ↗ |